三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

盘前交易 09-11 09:15:26 EDT

266.00

-13.02

-4.67%

盘前273.03

+7.03+2.64%

09:14 EDT

最高274.71	最低260.01	成交量29.01万
今开269.37	昨收279.02	日振幅5.27%
总市值4.99亿	流通市值4.99亿	总股本187.45万
成交额7,749万	换手率15.48%	流通股本187.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":266,"timestamp":1789070400000,"preClose":279.02,"halted":0,"volume":290130,"hourTrading":{"tag":"盘前","latestPrice":273.03,"preClose":266,"latestTime":"09:14 EDT","volume":2108,"amount":570188.4510400001,"timestamp":1789132487989,"change":7.03,"changeRate":0.026429,"amplitude":0.031504},"delay":0,"changeRate":-0.046663321625689855,"floatShares":1874486,"shares":1874486,"eps":0,"marketStatus":"盘前交易","change":-13.02,"latestTime":"09-11 09:15:26 EDT","open":269.37,"high":274.705,"low":260.01,"amount":77488111.8858,"amplitude":0.052666,"askPrice":274.38,"askSize":35,"bidPrice":269.99,"bidSize":35,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789133400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":266,"sharesOutstanding":3024486,"nav":278.651,"aum":522328218.83,"dividendRate":0.003776,"bidAskSpread":0.002964,"preHourTrading":{"tag":"盘前","latestPrice":273.03,"preClose":266,"latestTime":"09:14 EDT","volume":2108,"amount":570188.4510400001,"timestamp":1789132487989,"change":7.03,"changeRate":0.026429,"amplitude":0.031504},"postHourTrading":{"tag":"盘后","latestPrice":264.12,"preClose":266,"latestTime":"19:53 EDT","volume":1904,"amount":504475.6573,"timestamp":1789084425326,"change":-1.88,"changeRate":-0.007068,"amplitude":0.00782},"volumeRatio":0.9443493312965978,"impliedVol":0.9105,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"1139785537","title":"医疗保健板块动态：市场快讯综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1139785537","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139785537?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:23","pubTimestamp":1789115000,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场快讯，涵盖多只个股动态与行业趋势。这些信息分别在美东时间4:20、12:20和16:50通过道琼斯通讯社独家发布。2330 GMT——费雪派克医疗保健获得花旗的看涨背书，后者认为该公司既能提供增长潜力，又具备可靠的业绩兑现能力。花旗预计这家医疗器械制造商“中期内将实现可持续的两位数盈利增长，且相较于澳新地区的其他医疗保健类股票，其对消费者动态的敞口较低。”该股现报43.37新西兰元，下跌1.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","XLV","LABU","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114631909","title":"健康产业综合报道：市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1114631909","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114631909?lang=zh_cn&edition=full","pubTime":"2026-09-11 04:52","pubTimestamp":1789073579,"startTime":"0","endTime":"0","summary":"最新一期聚焦健康产业的市场快讯，于美东时间4:20、12:20及16:50通过道琼斯通讯社首发。当日，该公司股价下滑4.2%，收于8.72港元。马来西亚橡胶产品行业的盈利动能似乎正趋于稳定，而近年来股价的大幅回调使得估值更具吸引力，兴业投行分析师Andrew Lim在一份报告中如此表示。有鉴于此，兴业投行将该国橡胶产品行业的评级从“减持”上调至“增持”，并将贺特佳视为其首选标的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4585","BK4581","XBI","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110355096","title":"医疗保健板块市场综述：多空交织下的投资机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=1110355096","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110355096?lang=zh_cn&edition=full","pubTime":"2026-09-11 00:22","pubTimestamp":1789057364,"startTime":"0","endTime":"0","summary":"最新一轮医疗保健板块市场动态已出炉，涵盖多家亚洲主要医疗企业的股价走势、业绩展望与投资评级调整。市场反应方面，该股当日下跌4.2%，报收8.72港元。综合来看，亚洲医疗健康领域正呈现出多元化的投资叙事：从中国药企的临床数据催化，到新加坡医疗运营商的估值修复逻辑，再到印度医院的扩张故事以及马来西亚橡胶制品板块的估值重估，各细分赛道均蕴藏着不同的机遇与挑战。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","LABU","BK4588","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143873044","title":"医疗保健板块市场快讯综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1143873044","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143873044?lang=zh_cn&edition=full","pubTime":"2026-09-10 16:23","pubTimestamp":1789028599,"startTime":"0","endTime":"0","summary":"DBS集团研究部的Mark Kong与Nico Chen在一份报告中指出，石药集团未来两个月即将公布的临床数据演示，可能成为其股价近期走势的关键催化剂。分析师认为，公司主动参与数据发布，彰显了其对数据的充分信心。目前石药集团的估值约为2027年预测市盈率的18倍，较同行平均水平折价约28%，这为投资者提供了一个颇具吸引力的入场时机。DBS重新覆盖石药集团，给予\"买入\"评级，目标价定为13.70港元。该股今日下跌4.2%，报8.72港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","LABU","XBI","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554879","title":"传私募股权TPG(TPG.US)拟出售医疗保健软件公司Lyric 估值或达50亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666554879?lang=zh_cn&edition=full","pubTime":"2026-09-10 10:30","pubTimestamp":1789007455,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4550","BK4588","AAUM","XBI","IGM","PRVT","VHT","CGVV","LABU","PSP","XLV","BUYO","BK4585","BK4581","NOBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554821","title":"传私募股权TPG(TPG.US)拟出售医疗保健软件公司Lyric 估值或达50亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554821","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666554821?lang=zh_cn&edition=full","pubTime":"2026-09-10 10:30","pubTimestamp":1789007455,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，私募股权TPG正在探索出售医疗保健行业软件公司Lyric。他们提醒称，目前无法保证出售流程最终会促成Lyric交易。TPG于2022年以约22亿美元收购ClaimsXten。TPG于次年将该公司重新命名为Lyric。尽管具体增幅并未披露，但TPG表示，Lyric受益于AI的部署，而其拥有丰富数据集的业务模式将进一步放大这些收益。规模较小的上市同行Claritev股价在2025年9月至今年5月期间暴跌80%，原因是投资者担心AI会颠覆软件公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSP","IGM","PRVT","VHT","XBI","XLV","BK4550","NOBL","BK4588","LABU","AAUM","CGVV","BK4581","BK4585","BUYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666955978","title":"TPG考虑以50亿美元出售医疗保健软件公司Lyric","url":"https://stock-news.laohu8.com/highlight/detail?id=2666955978","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666955978?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:48","pubTimestamp":1789004922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4581","BK4550","LABU","XLV","BK4588","BK4585","VHT","XBI","CGVV","IGM","NOBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553284","title":"TPG探索出售医疗保健软件公司Lyric","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553284","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666553284?lang=zh_cn&edition=full","pubTime":"2026-09-10 07:38","pubTimestamp":1788997084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NOBL","XLV","BK4585","BK4588","VHT","BK4550","BK4581","IGM","LABU","CGVV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123618563","title":"医疗板块市场综述：多空观点交锋","url":"https://stock-news.laohu8.com/highlight/detail?id=1123618563","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123618563?lang=zh_cn&edition=full","pubTime":"2026-09-10 04:53","pubTimestamp":1788987194,"startTime":"0","endTime":"0","summary":"最新一期医疗板块市场快讯已发布，涵盖多家制药巨头的最新动态与分析师观点。本轮快讯于美国东部时间4:20、12:20和16:50在道琼斯通讯社独家刊出。**1107 ET**——加拿大皇家银行资本市场分析师在研报中指出，近期临床试验受挫意味着诺华制药必须在剩余管线产品的市场推广上做到近乎完美，抑或寻求并购交易。RBC给予该股\"与板块持平\"评级，目标价定为120瑞士法郎。诺华股价微跌0.3%，报111.44法郎。协和麒麟周二表示，该研究未能达到主要终点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4581","BK4588","LABU","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191167112","title":"医疗保健板块动态：市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1191167112","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191167112?lang=zh_cn&edition=full","pubTime":"2026-09-10 00:37","pubTimestamp":1788971848,"startTime":"0","endTime":"0","summary":"1107 GMT - 加拿大皇家银行资本市场分析师在研究报告中指出，近期临床试验受挫意味着诺华必须近乎完美地将其余管线产品推向市场，或寻求交易合作，但这家瑞士制药商不应操之过急。\"他们补充称，心血管药物pelacarsen和神经肌肉药物del-desiran的失败提高了诺华管线的门槛，因为这两款药物本是抵消即将到来的专利到期所造成销售损失的重要候选产品。RBC首次覆盖该股，给予\"与行业一致\"评级，目标价定为120瑞士法郎。该股下跌0.3%，报111.44法郎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","BK4581","XBI","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104370787","title":"医疗保健板块动态：市场快讯综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1104370787","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104370787?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:22","pubTimestamp":1788942151,"startTime":"0","endTime":"0","summary":"涵盖医疗保健板块的最新市场快讯，于美国东部时间4:20、12:20及16:50在道琼斯通讯社独家发布。该分析师表示，del-desiran原本是近期120亿美元收购Avidity的首个有力佐证。股价下挫4.7%，报2,251.0日元。2239 GMT——Petra Capital表示，由于美国食品药品监督管理局未对Echo IQ用于检测心力衰竭的工具EchoSolv HF给予批准，该公司股价今日可能遭遇抛售。FDA出具了“非实质性等同”判定。业界不乏企业在解决相关问题后最终获得FDA批准的案例。该机构将该股评级从“持有”下调至“卖出”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","BK4581","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196486882","title":"医疗保健板块快讯：市场动态一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1196486882","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196486882?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:57","pubTimestamp":1788901078,"startTime":"0","endTime":"0","summary":"聚焦医疗保健领域的最新市场快讯。本专栏内容仅通过道琼斯通讯社在美东时间4:20、12:20及16:50准时发布。受此消息影响，该公司股价应声下挫10%。这家美资投行认为，市场共识似乎低估了产品组合持续优化对利润率带来的积极影响。随着肾病药物Voyxact等自有资产逐渐接棒合作产品，成为这家日本制药企业的主要收入驱动力，Jefferies预测，在这一转型过程中，公司的利润增速将超越收入增速。为此，Jefferies将大冢的目标股价从12,700日元上调至14,000日元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","XLV","BK4581","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183339770","title":"摩根士丹利：Grindr医疗健康业务蕴藏巨大商机","url":"https://stock-news.laohu8.com/highlight/detail?id=1183339770","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183339770?lang=zh_cn&edition=full","pubTime":"2026-09-09 02:42","pubTimestamp":1788892936,"startTime":"0","endTime":"0","summary":"美东时间14:40——Grindr或将演变为一家披着约会应用外衣的医疗健康企业。该公司已借旗下Woodwork业务涉足远程医疗领域，该业务主要提供勃起功能障碍等病症的治疗药物。然而，摩根士丹利分析师在与Grindr管理层会晤后发布的研报中指出，Grindr的\"医疗健康雄心远不止于Woodwork\"。管理层认为，未来的健康相关收入机遇有望超越其核心业务规模。该公司正积极布局性传播疾病的预防与管理领域，并着眼于长远，旨在为平台用户提供全方位的临床医疗服务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU0029874061.USD","LU2347655156.SGD","LU1989772840.SGD","BK4516","LU2023251221.USD","KBWB","LU0528227936.USD","LU0912757837.SGD","BK4127","LU2264538146.SGD","LU2133065610.SGD","LU0006306889.USD","LU0053666078.USD","LU0234570918.USD","LU0882574139.USD","LU1162221912.USD","LU1244550577.SGD","IE00BZ1G4Q59.USD","XBI","LU1732800096.USD","LU0128526141.USD","LU0210528500.USD","BK4137","LU2111349929.HKD","BK4581","LU1989772923.USD","IAI","LU2028103732.USD","LU2357305700.SGD","BK4585","LU1064131342.USD","LU0971096721.USD","LU0158827948.USD","LU0795875086.SGD","LU1244550221.USD","LU1988902786.USD","LU1363072403.SGD","LU1548497426.USD","LU2271345857.HKD","IE00BKVL7J92.USD","LU0557290698.USD","BK4504","LU0314104364.USD","GRND","IE00B775SV38.USD","LU1720051017.SGD","LU1720051108.HKD","LU2487616109.SGD","LU0225283273.USD","LU1791710582.SGD","BK4077","LU0098860793.USD","LU0320765646.SGD","LU0158827781.USD","XLV","HCSG","LABU","LU1074936037.SGD","LU1732799900.SGD","LU2089284900.SGD","BK4588","LU0390134368.USD","LU0106261372.USD","LU1244550494.USD","LU0267386448.USD","LU0106831901.USD","BK4534","LU2089283258.USD","LU0795875169.SGD","LU1791710400.SGD","MS","IE00B3S45H60.SGD","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112978991","title":"医疗保健板块动态汇总：市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1112978991","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112978991?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:23","pubTimestamp":1788884589,"startTime":"0","endTime":"0","summary":"最新一期医疗保健板块市场快讯，涵盖行业动向与个股表现，于美国东部时间4:20、12:20及16:50通过道琼斯通讯社独家发布。该公司股价应声下跌10%。杰富瑞称，肾病药物Voyxact及其他自有资产正逐步取代合作产品，成为这家日本制药企业的主要收入驱动力。随着这一转型持续推进，该行预计利润增速将快于收入增速。杰富瑞将大冢目标价从12,700日元上调至14,000日元。该公司股价小幅上涨0.3%，报11,770日元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","LABU","BK4585","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665753923","title":"Tenet Healthcare（THC）拟私募发行15亿美元票据，置换到期债务","url":"https://stock-news.laohu8.com/highlight/detail?id=2665753923","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665753923?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:15","pubTimestamp":1788873326,"startTime":"0","endTime":"0","summary":"金吾财讯 | Tenet Healthcare（THC）周二公布债务操作计划，拟通过私募方式发行15亿美元、2034年到期的全新优先票据，用于对同等规模存量债务实施再融资。本次发行所得净资金，搭配公司现有现金，将全额赎回2027年11月到期，票面利率5.125%的优先有担保第一留置权票据。新票据属于无担保优先债务，和公司当前以及未来的其他无担保优先债务享有同等清偿顺位。本次票据发行还需要完成定价流程，并满足各类常规交割条件。票据仅依据相关证券豁免规则，面向合格机构投资者进行发售。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305820","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","THC","BK4185","LU0963586101.USD","LU0648000940.SGD","LU0130103400.USD","BK4585","XBI","BK4588","LU2324357040.USD","LU1201861165.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378596","title":"礼邦医药-B：AP308治疗IgA肾病新药临床申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378596","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665378596?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:20","pubTimestamp":1788870000,"startTime":"0","endTime":"0","summary":"9月8日，礼邦医药-B（09637）发布公告，公司自主研发的同类首创工程化重组IgA蛋白酶AP308，其新药临床试验申请已获FDA批准，将启动用于治疗IgA肾病的首次人体临床试验。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868261729.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868261729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09637","BK1191","LABU","09939","BK1161","BK1574","BK4585","BK4588","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665273123","title":"大家人寿9.8亿元投资接力基金 后者投向硬科技、医疗健康等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2665273123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665273123?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:25","pubTimestamp":1788866725,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","VHT","XBI","XLV","BK4581","BK4588","IXJ","LABU","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324454","title":"泰达生物(08189)与星辰通用签署战略合作框架协议 共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665324454?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:40","pubTimestamp":1788864000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物 公布，公司与湖南星辰通用机器人有限公司已签署战略合作框架协议。双方将本着平等自愿、优势互补、场景牵引、联合创新、资源共享、长期合作的原则，围绕医疗健康大模型与具身智能技术的深度融合，共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159760","BK4588","IXJ","XLV","BK4581","BK4550","WDRN","XBI","BK4585","08189","BK1113","VHT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665654324","title":"英国药品和医疗保健产品监管局已受理Biosplice公司关于洛雷西文特治疗膝骨关节炎的申请，并正式启动评估程序。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665654324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665654324?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:33","pubTimestamp":1788863626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["VHT","NOBL","BK4585","XLV","XBI","BK4588","BK4550","BK4581","CGVV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169238098","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1169238098","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169238098?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:25","pubTimestamp":1788855909,"startTime":"0","endTime":"0","summary":"不过，分析师注意到，公司对2030年后实现中个位数百分比增长的雄心未作任何表态。杰富瑞认为，即便近期一款多发性硬化症口服新药取得了成功，但若缺少del-desiran和del-brax这两款自Avidity Biosciences收购而来的药物，要确立市场对公司2030年代增长前景的信心仍面临重重挑战。该公司股价下挫10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XLV","XBI","BK4581","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1303},{"period":"1month","weight":-0.0523},{"period":"3month","weight":0.4892},{"period":"6month","weight":0.787},{"period":"1year","weight":2.3929},{"period":"ytd","weight":0.6689}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0165},{"period":"3month","weight":0.0217},{"period":"6month","weight":0.1443},{"period":"1year","weight":0.1619},{"period":"ytd","weight":0.1113}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.135885},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.001739},{"month":5,"riseRate":0.545455,"avgChangeRate":0.013816},{"month":6,"riseRate":0.75,"avgChangeRate":0.158596},{"month":7,"riseRate":0.583333,"avgChangeRate":0.031304},{"month":8,"riseRate":0.666667,"avgChangeRate":0.021527},{"month":9,"riseRate":0.25,"avgChangeRate":-0.068291},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}